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Allosteric receptor–receptor interactions in GPCR heteromers appeared to introduce an
intermolecular allosteric mechanism contributing to the diversity and bias in the protomers.
Examples of dopamine D2R heteromerization are given to show how such allosteric mech-
anisms significantly change the receptor protomer repertoire leading to diversity and biased
recognition and signaling. In 1980s and 1990s, it was shown that neurotensin (NT) through
selective antagonistic NTR–D2 like receptor interactions increased the diversity of DA
signaling by reducing D2R-mediated dopamine signaling over D1R-mediated dopamine
signaling. Furthermore, D2R protomer appeared to bias the specificity of the NTR orthos-
teric binding site toward neuromedin N vs. NT in the heteroreceptor complex. Complex
CCK2R–D1R–D2R interactions in possible heteroreceptor complexes were also demon-
strated further increasing receptor diversity. In D2R–5-HT2AR heteroreceptor complexes,
the hallucinogenic 5-HT2AR agonists LSD and DOI were recently found to exert a biased
agonist action on the orthosteric site of the 5-HT2AR protomer leading to the development
of an active conformational state different from the one produced by 5-HT. Furthermore,
as recently demonstrated allosteric A2A–D2R receptor–receptor interaction brought about
not only a reduced affinity of the D2R agonist binding site but also a biased modulation
of the D2R protomer signaling in A2A–D2R heteroreceptor complexes. A conformational
state of the D2R was induced, which moved away from Gi/o signaling and instead favored
β-arrestin2-mediated signaling.These examples on allosteric receptor–receptor interactions
obtained over several decades serve to illustrate the significant increase in diversity and
biased recognition and signaling that develop through such mechanisms.
Keywords: heterodimerization, G protein-coupled receptor, receptor heterodimers, biased signaling, biased
recognition, receptor diversity, receptor–receptor interactions, allosteric modulation
INTRODUCTION
Receptor diversity through the existence of receptor subtypes for
the same transmitter appears to be a general phenomenon among
GPCR and ion channel receptors. Receptor diversity in the case of
dopamine (DA) transmission is brought about by five DA recep-
tor subtypes, from D1R to D5R and by two isoforms of the D2R:
the long form (D2L) and the short form (D2S), two isoforms of
the D3R, and several (more than 10) isoforms of D4R; gener-
ated by alternative splicing of the same gene (1). The existence
of GPCR subtypes, e.g., for DA in a high and low affinity state,
probably reflects their role both in volume (extrasynaptic loca-
tion, low DA concentration) and synaptic (synaptic location, high
DA concentration) transmission, respectively. The relevance of
receptor–receptor interactions for receptor diversity in the GPCR
field was discussed in 1995 based on changes in the affinity of both
the high and low affinity state and in the proportion of receptors
in the two affinity states induced by the receptor–receptor interac-
tions in the plasma membrane (2). The reciprocal interactions
between receptor–receptor interactions and receptor sensitiza-
tion/desensitization in control of receptor affinity and signaling
were also presented (2). The origin of GPCR diversity has since
then been expanded by several groups (3). Today the receptor
diversity in the GPCR field has been tremendously increased with
identification of over 200 GPCR heteromers (4).
HISTORY OF RECEPTOR–RECEPTOR INTERACTIONS
The early work on the demonstration of neuropeptide–
monoamine receptor–receptor interactions in membrane prepa-
rations from different regions of the central nervous system (CNS)
(5–7) indicated, e.g., the existence of DA receptor subtype-specific
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interactions with neurotensin (NT) and cholecystokinin (CCK)
receptors in putative brain heteroreceptor complexes (8–15).
The stronger allosteric NTR–D2R and CCKR–D2R interactions
found in sections than in membrane preparations indicated the
requirement of intracellular mechanisms and/or a more intact
membrane structure for optimal receptor–receptor interactions
(16, 17).
NTR–D2R INTERACTIONS
Neurotensin was found to reduce the affinity of the high and
low affinity D2R agonist binding sites, which correlated with its
ability to counteract the DA agonist-induced inhibition of stri-
atal DA and GABA release and to induce neuroleptic actions
with relevance for its postulated anti-psychotic actions (2, 10,
18). NT did not modulate the D1 receptor binding characteris-
tics. Thus, by selective antagonistic NTR–D2R interactions NT
increases the diversity of DA signaling by changing the pattern of
D2R subtype-mediated signaling with D1 like receptor-mediated
signaling obtaining a dominant role over D2 like receptor signal-
ing (2). In other words in the striatum through this allosteric
receptor–receptor interaction in postulated NTR–D2 like het-
eroreceptor complexes, a bias had developed in DA transmission
toward D1R like vs. D2R like-mediated DA transmission. This
was accomplished through a prejunctional allosteric antagonis-
tic NTR–D2R autoreceptor interaction in striatal DA terminals
increasing DA release and a postjunctional allosteric antagonis-
tic NTR–D2R interaction mainly located on the cortico-striatal
glutamate nerve terminals but also on the striato-pallidal GABA
neurons increasing their activity and GABA release.
It was of substantial interest that the C-terminal NT(8–13)
fragment also potently and antagonistically modulated rat neos-
triatal D2Rs (19) and that neuromedin N (NN) also was a potent
inhibitory modulator of D2R agonist binding in rat neostriatal
membranes (20). In view of the higher potency of NN vs. NT
to modulate the affinity of neostriatal D2Rs, in contrast to the
higher potency of NT vs. NN to bind to the cloned NTRs (20),
the NN-activated neostriatal NT receptors involved in the affinity
regulation of the D2Rs, may have developed a bias toward NN
vs. NT in terms of affinity and/or potentially efficacy. This may
have been accomplished through a reciprocal allosteric D2R–NTR
interaction from the D2R protomer biasing the specificity of the
NT orthosteric binding site toward NN vs. NT binding in the
heteroreceptor complex.
It should be noticed that the antagonistic presynaptic but
not the postsynaptic NTR/D2R receptor–receptor interaction was
missing in the nucleus accumbens in contrast to dorsal striatum.
This led to increases in ventral striatal GABA release as in the
dorsal striatum but without increases in DA release (21). Instead,
reductions of accumbens DA release were observed likely at least
in part related to activation of GABA A receptors on the DA ter-
minals. Thus, regional differences in the microanatomy of the
NTR–D2R heteroreceptor complexes can have important regional
functional consequences at the local circuit levels of the ventral
and dorsal striatum leading to a differential regulation of the
striato-pallidal GABA outflow from these two regions by NT. The
NT-induced reduction of D2R signaling in the ventral striatum
therefore become stronger in the ventral striatum vs. the dorsal
striatum, which will favor anti-psychotic actions vs. development
of motor side-effects (11, 22).
CCK2R–D2R RECEPTOR INTERACTIONS
The pharmacological analysis indicated that only the CCK2Rs were
involved in the reduction of the affinity of the D2R agonist binding
sites in rat striatal membranes, in as much as, e.g., the CCK1 antag-
onist L364718 was ineffective in counteracting the increase of the
K d value by 1 nM of CCK-8 (16, 23). Thus, the CCK2R subtype,
can selectively interact in an inhibitory way with the D2R agonist
recognition, illustrating how receptor subtype development evolv-
ing both in the CCK and DA receptor family make possible, e.g., a
further diversity modulating the pattern of isoreceptor activity in
the DA and CCK receptor systems (2).
Intracerebral microdialysis in the dorsal striatum in combi-
nation with studies on DA release, gave in vivo correlates to the
CCK2R/D2R antagonistic receptor interaction in D2R recognition
at the presynaptic level in the striatal DA nerve terminal networks
(24). Thus, activation of presumable CCK2Rs may have reduced
the D2 autoreceptor affinity contributing to a reduction of the
apomorphine-induced inhibition of DA release. Studies on GABA
release within the nucleus accumbens supported the existence of
an antagonistic CCK2R/D2R interaction also within the postsy-
naptic cells by the demonstration that CCK-8 (1 µM) increased
both GABA and DA release (21). These antagonistic intramem-
brane interactions involving the postsynaptic D2 like receptors
probably take place in the striopallidal GABAergic neurons involv-
ing both the dorsal and ventral components of this pathway, the
ventral component being of particular interest in relation to schiz-
ophrenia in view of its role in controlling the output from the
limbic system (11, 22). The D2R is a major target for anti-psychotic
drugs.
It was of substantial interest that CCK-8, in contrast, increased
the affinity of dopamine for D2Rs in striatal membrane prepa-
rations in competition experiments with the D2R like antagonist
[3H]-raclopride vs. DA (23). The D1 receptor antagonist SCH-
23390 blocked this action and restored the ability of CCK-8 to
reduce D2R affinity. Thus, it appeared as if D1R activation in the
membrane preparations could alter the CCK-8-induced affinity
regulation of D2Rs from a reduction to an increase (23). Fur-
thermore, receptor autoradiographic analysis also demonstrated
differential modulatory effects of CCK-8 on the affinity of D2Rs,
depending on the use of a D2R agonist in saturation experiments
or a D2R antagonist in competition experiments using dopamine
as a displacer. The explanation for these seemingly contradictory
effects of CCK-8 on the D2Rs was proposed to be that CCK-8
reduced the affinity of D2Rs in the absence of D1R activation
by dopamine, and increased the affinity of D2Rs in the presence
of D1R activation (16). These differential effects could lead to
antagonistic and facilitatory allosteric effects on D2R-mediated
dopamine transmission, respectively taking place at the plasma
membrane level.
Previous work had proposed the existence of mosaics of recep-
tors in plasma membranes (9). The above results opened up the
possible existence of a receptor mosaic of D1R, D2R, and CCK2R
receptors in striatal and accumbens membrane preparations. The
discovery by George, O’Dowd and colleagues (25, 26) of D1R–D2R
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heteroreceptor complexes in the brain gave strong support to the
existence of higher order heteroreceptor complexes composed of
CCK2R–D1R–D2R heteroreceptor complexes. In such heterore-
ceptor complexes coactivation of D1R and D2R protomers may
via allosteric receptor–receptor interactions bias the orthosteric
binding site of the D2R to respond to the allosteric CCK2R–D2R
receptor–receptor interactions with an increase of affinity instead
of a reduction of affinity as seen upon CCK2R protomer acti-
vation alone. Further studies are needed, for example, using cell
lines cotransfected with CCK2R, D2R, and D1R receptor cDNAs
to provide direct evidence for the existence of CCK2R–D1R–D2R
heterotrimers with these integrative allosteric D1R–D2R–CCK2R
receptor–receptor interactions.
BIASED SIGNALING IN GPCRs
In 1995, Kenakin for the first time introduced the pioneering
concept of biased agonism or functional selectivity in the GPCR
field (27). It was proposed to reflect the agonist selective stabi-
lization of different active states of receptor conformation dif-
ferentially linked to signaling pathways (27–33). This phenom-
enon appears to be true for many GPCRs and has an impact
on drug discovery (28, 34, 35). GPCRs are regarded as allosteric
machines where allosteric modulators exert unique actions and
the allosteric effects can be quantified by the Ehlert allosteric
model and the Black/Leff operational model (28, 30). The ago-
nist related bias in GPCR systems was mainly introduced through
the studies on β-arrestin-mediated signaling and its relevance for
drug development (33, 36–40).
In 1995 (2), the concept of allosteric receptor–receptor inter-
actions in putative GPCR heteromers began to be introduced
adding an additional allosteric mechanism contributing to the
diversity and bias in the GPCR protomers. In recent years, allostery
at GPCR homomers and heteromers has been extensively cov-
ered and clearly discussed, especially by Smith and Milligan (41).
They point out the hallmarks for allosterism, namely that the
allosteric modulation is reciprocal, saturable, and shows probe
dependence.
The field of D2R heteroreceptor complexes and their rel-
evance for disease has been summarized in recent years (42,
43). The current review will give examples from recent work
on D2R heteromers mainly in cellular models indicating how
allosteric receptor–receptor interactions in receptor heteromers
may increase diversity and bias in the participating receptor
protomers of potential relevance for drug development.
D2R SIGNALING DYNAMICS THROUGH ALLOSTERIC
RECEPTOR–RECEPTOR INTERACTIONS IN D2R–NTR1
RECEPTOR HETEROMERS
Recent biochemical, histochemical, and co-immunoprecipitation
experiments have indicated the existence of antagonistic dopamine
D2R and neurotensin 1 (NTR1R) receptor–receptor interactions
in the dorsal and ventral striatum using inter alia NTR1 receptor
antagonists (44, 45). NTR–D3R receptor–receptor interactions
may potentially also exist (45). The discovery of the existence
of both D2LR–NTR1R and D2SR–NTR1R heteromers was made
under basal conditions in living HEK293T cells by means of bio-
luminescence resonance energy transfer (46). Through confocal
laser microscopy, they were also shown to be colocated in the
plasma membrane of these cells.
Based on a bioinformatic approach, Tarakanov and Fuxe (47)
deduced a set of protriplet aminoacid homologies that contribute
to receptor–receptor interactions. This bioinformatic analysis sug-
gests the existence of a basic set of three homology amino acid
protriplets (TVM, DLL, and LRA) in the two participating recep-
tor protomers that contribute to the formation of the D2R–NTR1R
heteromers by being part of the receptor interface (46).
The CREB reporter gene assay indicated that the NTR ago-
nist JMV 449 (10 and 30 nM) markedly reduced the potency of
the D2R like agonist quinpirole to inhibit the forskolin-induced
increase of the CREB signal (Figure 1). Thus, it seems that the
antagonistic allosteric D2R–NTR1 receptor–receptor interaction
previously observed on striatal D2R recognition [see review (10)]
also exists in the regulation of the D2R/Gi/o coupling inhibiting
the adenylyl cyclase (AC) activity, which leads to a reduction of
the CREB-mediated signaling (46). These results help explain the
antagonistic functional interactions seen with NT and DA ligands
in microdialysis and behavioral experiments (48, 49). Thus, the
allosteric waves, induced through the NT agonist activation of
the orthosteric site of the NTR1 receptor, pass over the receptor
interface and transfer the D2R protomer into a conformational
state with reduced D2R affinity and Gi/o coupling to the adenylate
cyclase.
It is of interest that at 30 nM of the NT agonist used quinpirole
could no longer fully counteract the NT agonist action even in the
high concentrations. Furthermore, at 50 nM the NT agonist not
only counteracted the D2R agonist-induced inhibition but even
significantly increased the CREB signal vs. control. These results
open up the possibility that the conformational states induced
and stabilized in the D2R protomer by the NT agonist via allosteric
receptor–receptor interaction also involves a Gs coupling of the D2
agonist quinpirole-activated D2R protomer besides the reduction
of the Gi/o coupling (46). Thus, a biased modulation of the sig-
naling pathways of the quinpirole-activated D2R protomer in the
D2R–NTR1 heteromer may have developed through the allosteric
receptor–receptor interaction (28, 34).
In contrast, the NT agonist was found to markedly increase
the quinpirole potency to activate the MAPK pathway as studied
with luciferase reporter gene assay measuring the degree of SRE
activity as well as with ERK1/2 phosphorylation by means of in
cell western assays (Figure 1). The NT receptor agonist-induced
enhancement of the D2R agonist-produced increases of MAPK
signaling was blocked by the NT receptor antagonist, SR142948.
One mechanism for this enhancement of the MAPK signaling
of the D2R receptor may be the NT receptor agonist-induced
activation of PKC via the Gq–PLC β–PKC pathway (46). Ago-
nist activation of D2Rs is also known to activate PKC involving
Gi/o and β-arrestin binding to the D2R and signaling followed
by activation of PLC-β (Figure 1). However, this mechanism may
be increased in the D2R protomer of the D2R–NTR1 heteromer
through the antagonistic allosteric receptor–receptor interaction
favoring β-arrestin binding and signaling (see above). Thus, a syn-
ergistic activation of PKC by D2R and NTR1R at the level of the
signaling cascades may be the mechanism for the ability of ago-
nist coactivation of the D2R and NTR1R to markedly enhance
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FIGURE 1 | Illustration of changes in cAMP–pCREB and MAPK–SRE
signaling pathways induced by agonist actions at NTR1–D2R
heterodimers and at NTR1 receptor homodimers and D2 receptor
homodimers. NT produces via an antagonistic allosteric NTR1–D2
receptor–receptor interaction a reduction in the D2R agonist-induced
activation of Gi/o leading to a marked reduction of activity in the
cAMP–pCREB pathway. Instead, β-arrestin-mediated internalization and
signaling may be favored due to a biased modulation of the D2R protomer
via the allosteric receptor–receptor interaction in the heterodimer (see left
part). The coagonist treatment also results in a facilitatory interaction in the
activation of the MAPK–SRE pathway, which may take place in this
signaling pathway at the level of PKC. Thus, the NTR1 agonist can activate
the NTR1 protomer, which activates the MAPK–SRE pathway via
Gq/11–PLC–PKC. The D2R agonist can target the D2R protomer and
produce its activation of the MAPK–SRE pathway via several mechanisms,
including β-arrestin–PI3k–PKC or β-arrestin–Scr–PKC (see left part). It should
also be noted that this facilitatory interaction can also involve the D2R
receptor homodimers and the NTR1 receptor homodimers (see right part).
However, the facilitatory interaction may become stronger in the NTR1–D2R
heteromer signaling since the NT protomer-induced antagonism of D2R
protomer-mediated Gi/o signaling may favor the switch toward β-arrestin
recruitment and signaling.
D2R signaling via the MAPK pathway and can involve also the D2
and NTR1 homodimers (Figure 1). In this case, there is likely no
allosteric receptor–receptor interaction involved as proposed for
the NTR1 protomer-mediated antagonism of the Gi/o signaling
from the D2R protomer to AC.
Taken together, the results obtained in this cellular model
give strong support to the view that the NTR1 protomer of
a D2R–NTR1 heteromer upon activation by a NTR1 agonist
via an allosteric receptor–receptor interactions counteracts D2R
agonist-induced D2 protomer signaling over Gi/o–AC–PKA–
CREB. A biased modulation of the D2R protomer signaling may
also develop through this allosteric receptor–receptor interaction.
Thus, an increased activity in the CREB pathway over basal activity
was observed upon combined treatment with quinpirole and the
NTS agonist, which can be explained by a coupling of the D2R
protomer to Gs instead of to Gi/o. Instead, the increased activity
of the MAPK pathway after coactivation of the D2R and NTR1
receptors likely involves synergistic interactions with PKC at the
level of the signaling cascades linked to the heteromer and likely
also the D2 and NTR1 homodimers.
The results obtained in the cellular models also have a thera-
peutic relevance for treatment of schizophrenia since they indicate
that the NTR1 protomer in the D2R–NTR1 heteroreceptor com-
plex of the ventral striatum can reduce D2R protomer signaling
over the Gi/o–AC–CREB pathway. Thus, development of NTR1
agonists and positive allosteric modulators targeting if possible
preferentially the NTR1 protomers represents a relevant strategy.
This includes also a potential for reduced side-effects based on
the DA hypothesis of schizophrenia and the fact that mainly the
D2R protomers in the D2R–NTR1 heteroreceptor complexes are
affected (50).
ACTIONS OF HALLUCINOGENIC 5-HT2AR AGONISTS ON THE
D2R–5-HT2AR HETERORECEPTOR COMPLEX
Biophysical methods demonstrated dopamine D2R–5-HT2AR
heteromers in cellular models after cotransfection of the two
receptors (51, 52). This was an interesting finding since atypical
anti-psychotic drugs block both D2R and 5-HT2AR receptors (53)
and the D2R–5-HT2AR heteroreceptor complexes could therefore
represent a novel target for anti-psychotic drugs.
As studied in HEK-293T27 cells, the 5-HT2AR protomer-
mediated phospholipase C (PLC) activation by 5-HT in this het-
eromer was synergistically enhanced by the concomitant activation
of the D2LR protomer by the D2R agonist quinpirole based on an
NFAT-luciferase reporter gene assay (Figure 2). A specific and
significant elevation of the intracellular calcium levels was also
observed when both receptor protomers were simultaneously acti-
vated (51). It seems possible that the mechanism involved could
be an allosteric D2R–5-HT2AR receptor–receptor interaction
increasing the efficacy of the serotonin 5-HT2AR protomer–Gq
complex to activate the PLC-initiated cellular signaling pathway.
In contrast, using a CRE-luciferase reporter gene assay the D2R
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FIGURE 2 | Illustration of the biased agonist action of the
hallucinogenic 5-HT2A agonists LSD and DOI at the 5-HT2A
protomer of the 5-HT2A–D2LR heterodimer, which leads to
enhanced Gi/o signaling over the D2R protomer producing an
enhanced inhibition of the AC–PKA–CREB pathway. In contrast, the
standard 5-HT2A agonist TCB2 did not produce a modulation of the D2R
agonist-induced inhibition of the AC–PKA–CREB pathway and the
endogenous ligand 5-HT significantly reduced the signaling of this
pathway. A biased 5-HT2A agonism with DOI was also observed in the
facilitatory D2LR–5-HT2A receptor–receptor interaction of the heteromer,
which enhances 5-HT2A signaling over Gq/11–PLC when using 5-HT and
TCB2 as 5-HT2A agonists. Thus, when using DOI as a 5-HT2A agonist, a
D2R agonist instead diminished 5-HT2A protomer signaling over the
Gq/11–PLC pathway.
protomer-mediated AC inhibition by the D2R agonist quinpirole
was reduced by the 5-HT-induced activation of the 5-HT2AR pro-
tomer. In this case, the mechanism may be a 5-HT activation of
an antagonistic allosteric 5-HT2AR–D2R receptor–receptor inter-
action, which reduces the efficacy of the quinpirole D2R–Gi/o
complex to inhibit the AC-initiated signaling pathway (51). Thus,
bidirectional allosteric receptor–receptor interactions may be in
operation in this heteromer.
Instead, quinpirole induced activation of the D2R protomer
reduces the efficacy of the hallucinogenic 5-HT2AR agonist
DOI [(±)-2,5-dimethoxy-4-iodoamphetamine] induced Gq/11
coupling of the 5-HT2AR protomer to the PLC signaling pathway
as seen from the diminished production of inositol phosphate
by DOI (Figure 2) (54). This is different from the case when
the endogenous ligand 5-HT was used to activate the 5-HT2AR
(see above). One explanation is that the hallucinogenic 5-HT2AR
agonist stabilizes a different active conformation of the 5-HT2AR
protomer compared with the endogenous ligand 5-HT, which
responds to the quinpirole induced allosteric D2-5–HT2AR
receptor–receptor interactions with a reduction in the efficacy
of the DOI–5-HT2AR–Gq complex to activate the PLC signal-
ing pathway. Thus, DOI may be a biased agonist at the 5-HT2AR
protomer (28, 30).
Based on the above results, we explored if the allosteric coun-
teraction of D2R agonist induced D2R protomer inhibition of
the AC signaling pathway through the 5-HT-activated 5-HT2AR
protomer was altered when using the known hallucinogenic high
affinity 5-HT2AR agonists lysergic acid diethylamide (LSD) and
DOI (55). The 5-HT receptor agonist activity of hallucinogens
of the indolealkylamine and of the phenylethanolamine type in
the CNS was first described in the late 60s and early 70s (56–
59). Such an alteration if enhancing D2R protomer function in
www.frontiersin.org May 2014 | Volume 5 | Article 71 | 5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fuxe et al. Bias through GPCR heteroreceptor complexes
the D2R–5-HT2AR heteromer may contribute to their psychotic
actions. We tested this hypothesis in HEK293-T27 cells and ven-
tral striatum (60) studying 5-HT2AR–D2R interactions using LSD
and DOI and a standard 5-HT2AR agonist TCB2 (61) to modulate
D2R protomer binding and signaling (Figure 2).
Indications were obtained for the existence of D2R–5-HT2AR
heteroreceptor complexes also in discrete regions of the ventral
and dorsal striatum with proximity ligation assays (PLA) (60).
Using double immunofluorescence procedures with green and red
immunofluorescence for D2Rs and 5-HT2ARs, respectively, it was
possible to observe a widespread appearance of punctuate yellow-
ish fluorescence in the dorsal striatum and the nucleus accumbens
likely representing to a large extent a dendritic colocalization of
the two receptors.
The hallucinogenic 5-HT2AR agonists LSD and DOI but not
the standard 5-HT2AR agonist TCB2 produced an enhancement
of the D2R agonist induced increase of D2R protomer affin-
ity, density, and signaling via Gi/o to inhibit the AC–PKA–CRE
pathway (Figure 2). CRE-luciferase reporter gene assays and [3H]-
raclopride binding experiments were used (60). In contrast, as
previously shown the endogenous ligand 5-HT instead caused
an antagonistic allosteric 5-HT2AR–D2R receptor–receptor inter-
action on D2R protomer signaling in these receptor heteromers
in HEK293-T27 cells. TCB2 in the range of 10–100 nM, which
can fully activate the 5-HT2AR signaling pathways (62) could not
modulate the D2R protomer recognition and signaling in [3H]-
raclopride binding and CRE reporter gene assays, respectively (60).
Therefore, the enhancement of D2R signaling over the AC–PKA–
CRE pathway produced by LSD and DOI cannot be produced by
crosstalk in the signaling cascades of the D2R and 5-HT2AR recep-
tors (Figure 2). The actions of the two hallucinogens were blocked
by the 5-HT2AR receptor antagonist ketanserin.
Taken together, the results suggest that the LSD and DOI
exert a biased agonist action on the orthosteric site of the 5-
HT2AR protomer leading to the development of an active con-
formational state different from the one produced by 5-HT.
This state will then induce a different allosteric 5-HT2AR–D2R
receptor–receptor interaction leading not to antagonistic but to
facilitatory allosteric interactions, which enhances D2R protomer
signaling leading to increased Gi/o-mediated inhibition of the
AC–PKA–CRE signaling pathway (Figure 2).
This biased agonist action produced by LSD and DOI at the
5-HT2AR protomer leading to altered receptor–receptor inter-
actions with the D2 protomer is probably also the mechanism
for the ability of DOI and LSD to increase the density and ago-
nist affinity of the D2Rs in membranes from D2R and 5-HT2AR
cotransfected HEK293-T27 cells and from the ventral striatum,
actions blocked by ketanserin. Thus, there may exist cryptic D2R
protomers of the D2R–5-HT2AR heteroreceptor complex in the
membranes, which cannot bind the D2 like receptor antagonist.
However, after the biased agonist action of DOI and LSD an
allosteric change develops in the cryptic D2R protomers and their
orthosteric binding sites become available to binding by [3H]-
raclopride. Thus, the biased 5-HT2AR actions of LSD and DOI
at the 5-HT2AR protomer lead both to increased D2R density
and increased D2R agonist affinity in the high affinity agonist
binding site.
In view of these findings, it seems possible that the psychotic
actions of the 5-HT2AR agonist hallucinogens (63) can involve
enhancement of D2R protomer signaling in the D2R–5-HT2AR
heteroreceptor complex in the nucleus accumbens. This may give a
novel understanding of the molecular mechanism underlying the
therapeutic effects of atypical anti-psychotic drugs. Thus, many
atypical anti-psychotics like risperidone and clozapine are inter
alia characterized by their higher potency to block 5-HT2AR than
D2Rs (53, 64–66). It can be speculated that in some forms of schiz-
ophrenia this pathological facilitatory 5-HT2AR–D2R interaction
has developed in the D2R–5-HT2AR heteroreceptor complex lead-
ing to increased D2R protomer recognition and signaling. One
advantage of many atypical anti-psychotics can therefore be that
they can counteract the D2R protomer signaling at low doses in the
D2R–5-HT2AR heteroreceptor complex through their blockade of
the 5-HT2AR protomers. This will block the facilitatory receptor–
receptor interaction and lead to reduced D2R protomer recog-
nition and signaling. In this way, anti-psychotic effects against
positive symptoms of schizophrenia can develop in doses of atyp-
ical anti-psychotics that will not fully block several other D2R
populations not forming heteroreceptor complexes with 5-HT2AR
receptors in the CNS. The blockade of certain of these D2Rs can be
involved in producing cognitive and extra-pyramidal side-effects
of typical antipsychotics like haloperidol (64).
DYNAMICS AND BIAS THROUGH ANTAGONISTIC
RECIPROCAL RECEPTOR–RECEPTOR INTERACTIONS IN
A2A–D2 HETERORECEPTOR COMPLEXES
Adenosine A2A receptor (A2AR)-dopamine D2 receptor het-
eromerization was demonstrated by means of biochemical and
biophysical methods, namely co-immunoprecipitation, biolumi-
nescence resonance energy transfer (BRET), and fluorescence res-
onance energy transfer analyses, upon transient cotransfection of
the two receptors in cell lines (67–71). A2AR–D2R heteroreceptor
complexes were later on also found in the striatum using the PLA
technique (72, 73).
Antagonistic A2AR–D2R receptor–receptor interactions in stri-
atal membrane preparations were early on demonstrated after
incubation with A2AR agonist CGS21680 as seen from demon-
strated by the reduction of the affinity of the high affinity D2R
agonist-binding site (74). With receptor autoradiography, strong
reductions in affinity were observed after A2AR agonist treatment
in the nucleus accumbens core and shell of the rat (75). Significant
increases in the EC50 values were also observed in the human cau-
date after incubation of the sections with CGS21680. Furthermore,
the antagonistic A2AR–D2R interaction in A2AR–D2R heteromers
diminished the Gi/o-mediated signaling of the D2R (71, 76).
In D2R–A2AR cotransfected neuroblastoma cells, coactivation
of A2AR and D2R resulted in the coaggregation, cointernalization,
and codesensitization of the A2AR and D2R (77). However, it was
unknown how the scaffolding protein β-arrestin2, was involved in
these events.
Recently it was shown that that the activation of the A2AR–
D2R interaction also favors β-arrestin2 recruitment to the D2LR
protomer with subsequent increase in cointernalization (68).
Thus, this allosteric A2AR–D2R receptor–receptor interaction
brings about a biased modulation of the D2 protomer signaling.
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A conformational state of the D2R protomer is induced, which
moves away from Gi/o signaling and instead favors binding of
β-arrestin2 and β-arrestin2-mediated signaling (68, 78, 79). This
change in functional selectivity can in part explain the reduced
time onset of Akt phosphorylation after the A2AR–D2R coactiva-
tion followed by a rapid dephosphorylation (68). The decrease in
Akt phosphorylation can be caused by the recruitment of PP2A to
the D2R–GRK–β-arrestin2–Akt complex (80).
In view of above, the A2AR agonist CGS 21680, which
demonstrates atypical anti-psychotic properties (81) may in part
exert anti-psychotic properties by increasing β-arrestin2 signal-
ing over the D2R. In agreement, the finding was made in 2011
that β-arrestin-biased dopamine D2R ligands for probing signal
transduction pathways is essential for anti-psychotic efficacy (82).
D2R-mediated suppression of NMDA-induced depolarized
plateau potential is mediated by the suppression of Cav1.3a L-type
calcium channel current induced through the D2R–PLC signaling
cascade involving the activation of calcineurin and dephosphory-
lation of these channels (83). It is of particular interest that also this
D2R signaling event can be blocked by A2AR activation likely via
the antagonistic allosteric receptor–receptor interaction in the stri-
atal A2AR–D2R heteroreceptor complexes (83). Thus, by means
of competitive peptides mimicking the serine-containing epitope
it was possible to block the ability of the A2AR to counteract
the effects of D2R activation performing perforated-patch-clamp
recordings on brain slices.
The glutamate hypothesis of schizophrenia states the existence
of a reduced NMDA receptor function in schizophrenia, which
may contribute to reduce firing of the ventral striato-pallidal
GABA systems contributing to psychotic symptoms. This deficit
may at least in part be restored by A2AR agonists. Taken together,
the results strongly indicate that biased modulation of the D2R
protomer by the A2AR protomer in the A2AR–D2R heterorecep-
tor complex within the nucleus accumbens can be a promising
mechanism for drug development in psychosis.
The existence of an electrostatic interaction between the C-
terminal tail of the A2AR and the third intracellular loop (IL3) of
the D2R was demonstrated to be importantly involved in the A2AR
protomer-mediated allosteric effects on the D2R protomer recog-
nition, signaling, and trafficking (69, 70). Electrostatic bonds of
covalent-like strength are formed in this interaction and a detailed
mutational analysis was made in the A2AR C-terminal tail (69, 70,
84, 85).
Recently evidence was obtained for the existence of a reciprocal
allosteric communication from the D2R to the A2AR protomer of
the A2AR–D2R heteromer (86). This allosteric receptor–receptor
interaction was found to be mostly mediated by two regions
rich in arginine known to give with positive charges, located in
IL3 of the D2R. The negative allosteric modulation by the D2R
on A2AR agonist binding was shown in a real-time mode. It
was possible to determine that D2R activation in part inhibited
and also slowed the binding of the fluorescent A2AR agonist
to the A2AR (86). The interaction was abolished by mutating
the IL3 of the D2R. The Arg residues (217–222 and 267–269)
in IL3 of the D2R were demonstrated to play a major role in
the antagonistic allosteric D2R–A2AR receptor–receptor interac-
tion. This allosteric receptor–receptor interactions makes possible
also an inhibitory modulation by the D2R protomer of the A2AR
protomer binding and function.
Taken together, the dynamics through allosteric communica-
tion is such that when the A2AR protomer is activated by an A2AR
agonist it will not only increase A2AR signaling but also produce a
reduction of D2R protomer recognition and a biased modulation
of D2R protomer signaling. This will involve a dynamic reduc-
tion of D2R protomer-mediated Gi/o signaling and an increase
in D2R protomer-mediated β-arrestin2 signaling. Thus, an inte-
grative signal is produced in the receptor heteromer in which the
major D2R signal opposing A2AR protomer function is strongly
reduced through which a further dominance of A2AR protomer
Gs-mediated signaling develops. In the case when the D2R pro-
tomer is activated by agonist, an inhibitory allosteric reciprocal
D2R–A2AR receptor–receptor interaction develops leading to a
reduction of A2AR recognition and signaling. Again an integra-
tive signal develops with a strong D2R protomer signal which
through the allosteric communication in the heteromer becomes
even more dominant via reduction of the opposing A2AR signal.
These events take place rapidly in the plasma membrane. As the
A2AR and D2R protomer signals progress into the cytoplasm they
will be further integrated in the cytoplasmic signaling cascades,
especially the AC–PKA–CRE pathways together with the signals
from the A2AR and D2R homodimers (87).
BIASED RECOGNITION IN GalR1–GalR2 HETEROMERS
The three cloned galanin (Gal) receptors show a higher affin-
ity for Gal than for Gal N-terminal fragments like Gal (1–15)
(88). An interesting development of this field was the demon-
stration of specific N-terminal Gal fragment (1–15) binding sites
in the rat brain indicating a relevant role of Gal fragments in
Gal communication in the CNS, especially in dorsal hippocam-
pus, neocortex, and striatum (89). These areas have a low den-
sity of high affinity Gal (1–29) binding sites. Our hypothesis is
that these N-terminal Gal fragment preferring sites may be the
result of formation of GalR1/GalR2 heteromers. In this heteromer
through allosteric modulation, a conformational state is formed in
which their Gal recognition sites may be converted into Gal frag-
ment preferring binding sites with reduced affinity for Gal (1–29)
(42, 90, 91).
Recently it was in fact possible to detect GalR1/GalR2 het-
eromers in cotransfected Hela cells by in situ PLA and in cotrans-
fected HEK293 cells with BRET methodologies (92). A functional
validation was also achieved for the existence of GalR1/GalR2 het-
eromers, which preferentially bind N-terminal Gal (1–15). Using
CRE-luciferase reporter gene assays, it was found in GalR1/GalR2
transfected cells that Gal1–15 was significantly more potent than
Gal (1–29) in reducing the forskolin-induced increase of luciferase
activity through the direct activation of AC (Figure 3). Such evi-
dence was not obtained in singly transfected cells (GalR1 or GalR 2
alone). These results suggest that the agonist activation site of the
GalR1–GalR2 heteromer has a preferential affinity for the Gal (1–
15) fragment (92). Similar results were obtained in SRE-luciferase
reporter gene assays (Figure 3). Gal (1–15) was found to be sig-
nificantly more potent than Gal1–29 in increasing SRE activity
in GalR1 and GalR2 cotransfected cells. This was not the case in
singly transfected cells.
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FIGURE 3 | Illustration of the biased recognition of the GalR1–GalR2
heterodimer. Thus, this heteromer preferentially recognizes the gal fragment
1–15 vs. galanin 1–29 in contrast to the GalR1 homodimer and the GalR2
homodimer. This is seen from the increased potency of gal 1–15 to reduce
activity in the AC–PKA–CREB pathway and increase activity in the MAPK–SRE
pathway in cotransfected GalR1 and GalR2 HEK cells vs. GalR1 and GalR2
singly transfected cells. The activity of the GalR2 protomer in the Gq/11–PLC
pathway of the GalR–GalR2 heteromer remains to be determined.
Taken together, these results obtained in cellular models open
up the possibility that GalR1/GalR2 heteroreceptor complexes
exist also in the brain and can be the targets for N-terminal
Gal1–15, especially in the hippocampus, neostriatum, and cere-
bral cortex. Thus, allosteric communication across the receptor
interface in the GalR1/GalR2 heteroreceptor complex appears to
lead to bias in their orthosteric binding sites toward the Gal1–
15 fragment vs. Gal1–29 (Figure 3). This is of special interest
for drug development since it was recently reported that Gal1–15
given intraventricularly in the rat produced marked depression-
like behavior in the forced swim test and anxiogenic-like effects in
the open field (93).
CONCLUDING REMARKS
The allosteric receptor–receptor interactions in the D2 heterore-
ceptor complexes presented produce upon agonist activation of
the partner protomer significant changes in D2R protomer recog-
nition and/or signaling. Thus, this allosteric mechanism through
intermolecular interactions changes the D2R protomer repertoire
in these complexes diversifying and biasing the D2R function
upon agonist activation of the partner protomer. In the case of
the NTR–D2R and A2AR–D2R complexes, the NT peptide and
A2AR agonist, respectively, both reduced the D2R agonist affin-
ity and reduced the D2R signaling over Gi/o. Not only was the
efficacy of the Gi/o signaling reduced in the A2AR–D2R complex
but it also switched toward β-arrestin-mediated signaling giving
a new bias to the D2R protomer signaling in this complex upon
agonist activation of the A2AR protomer. This underlines the view
that the D2R protomer can also change and bias its signaling
pattern and thus its function by the allosteric receptor–receptor
interaction [see also Ref. (25)]. A change in the signaling pattern
of the D2R protomer may also have developed in the NTR–D2R
complex after high concentrations of NT, in this case toward Gs-
mediated D2 protomer signaling. It should be noticed that the
NTR and A2AR do not physically interact with the D1 receptors to
antagonize their recognition and signaling. Therefore, activation
of the NTR and A2A protomers in the D2 heteroreceptor com-
plexes discussed will bias DA signaling in the networks toward
D1R-mediated transmission.
The work on the D2R–5-HT2A heteroreceptor complex using
5-HT and the D2like agonist quinpirole illustrated two hall-
marks of allostery, reciprocity, and probe dependence. Firstly 5-HT
reduced the efficacy of the D2R agonist-activated D2R protomer–
Gi/o complex to inhibit the AC–PKA pathway while quinpi-
role synergistically enhanced the ability of the 5-HT-activated
5-HT2A–Gq complex to activate PLC. The probe dependence was
demonstrated by the use of the hallucinogenic 5-HT2A agonists
LSD and DOI but not by the standard 5-HT2A agonist TCB2. In
this case, the DOI-induced PLC signaling of the 5-HT2A pro-
tomer became reduced by quinpirole. Furthermore, DOI and
LSD enhanced the D2R agonist quinpirole induced inhibition of
the AC–PKA–CRE pathway and increased the density and ago-
nist affinity of the D2 protomer. Thus, LSD and DOI probably
induced a biased action on the orthosteric binding site of the
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5-HT2A protomer leading to an active conformational state differ-
ent from the one produced by 5-HT and TCB2. This enhancement
of D2R agonist-induced D2R protomer signaling and increase in
D2R recognition can contribute to the hallucinogenic and psy-
chotic actions of LSD and DOI in view of the documented role
of enhanced D2R recognition and signaling in schizophrenia. In
contrast, the agonist activation of the NTR and A2AR protomers
reduced the affinity of the D2R protomer and its Gi/o-mediated
signaling in the respective heteroreceptor complexes (see above).
CCK2R agonists at the CCK2R protomer of putative CCK2–
D2 heteroreceptor complexes also reduced the affinity of the D2R
protomer but only in the absence of D1R activation by dopamine.
However, this allosteric modulation switched to an increase in
the affinity of D2R protomer in the presence of D1R activa-
tion. These differential effects illustrated the diversification of the
CCK2R allosteric modulation of the D2R protomers into antag-
onistic or facilitatory allosteric effects dependent on the agonist
activation of the D1R. These results can be explained by the exis-
tence of higher order heteroreceptor complexes of D1R, D2R, and
CCK2R receptors in striatal and accumbens membrane prepara-
tions in which the activation of D1R protomers determines the
outcome of the allosteric modulation of the D2R protomer. The
complex allosteric receptor–receptor interactions in such puta-
tive heterotrimeric receptor complexes remain to be determined,
which is true also for other higher order heterotrimeric recep-
tor complexes like the A2A–D2–mGluR5 (94) and A2A–D2–CB1
(95). This will determine the impact of the allosteric communica-
tion on diversity and bias of the partner protomers and the pattern
of signaling that may develop from the receptor protomers of such
higher order heteroreceptor complexes.
GalR1/GalR2 heteroreceptor complexes are included to indi-
cate that clearcut-biased recognition can develop in such com-
plexes becoming major targets for N-terminal Gal1–15 in the brain
with reduced recognition of Gal. Thus, allosteric communication
across the receptor interface in the GalR1/GalR2 heteroreceptor
complexes appears to lead to bias in their orthosteric binding sites
toward binding the Gal1–15 fragment vs. Gal1–29. They appear
to become Gal1–15 receptors and may be named Gal fragment
receptors.
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